特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

遺伝子治療の世界市場 - 2024年までの予測:非ウイルスベクター (オリゴヌクレオチド)、ウイルスベクター (レトロウイルスベクター、アデノ随伴ウイルスベクター)

Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024

発行 MarketsandMarkets 商品コード 923297
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
遺伝子治療の世界市場 - 2024年までの予測:非ウイルスベクター (オリゴヌクレオチド)、ウイルスベクター (レトロウイルスベクター、アデノ随伴ウイルスベクター) Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024
出版日: 2020年01月20日 ページ情報: 英文 136 Pages
概要

世界の遺伝子治療市場は、2019年の38億米ドルから、2024年までに130億米ドルに達すると予測されており、予測期間中のCAGRは27.8%と推定されています。がんやその他の標的疾患の発生率の高さ、償還の利用可能性、新製品の発売は、この市場の成長を牽引する主要な要因です。さらに、市場企業の強力な製品パイプラインが、今後数年間で大きな成長機会を提供することが期待されています。ただし、治療の高コストは、今後数年間で市場の成長をある程度妨げると予想されます。適応別では、神経疾患セグメントが最大のシェアを占めました。ベクター別では、ウイルスベクターセグメントが、予測期間中に最大の成長を記録すると予想されます。地域別では、北米が市場を支配し続けます。

当レポートでは、世界の遺伝子治療市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

923297_4.1 GENE THERAPY MARKET OVERVIEW_FIGURE 8

目次

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 遺伝子治療市場の概要
  • 北米 - 遺伝子治療市場:ベクター別
  • 遺伝子治療市場の地理的概要

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 市場機会
    • 課題

第6章 遺伝子治療市場:ベクター別

  • イントロダクション
  • 非ウイルスベクター
    • オリゴヌクレオチド
    • その他の非ウイルスベクター
  • ウイルスベクター
    • レトロウイルスベクター
    • アデノ随伴ウイルスベクター
    • その他のウイルスベクター

第7章 遺伝子治療市場:適応別

  • イントロダクション
  • 神経疾患
  • がん
  • 肝疾患
  • デュシェンヌ型筋ジストロフィー
  • その他の適応

第8章 遺伝子治療市場:デリバリー方法別

  • イントロダクション
  • 生体内 (in vivo) 遺伝子治療
  • 生体外 (ex vivo) 遺伝子治療

第9章 遺伝子治療市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第10章 競合情勢

  • 概要
  • 市場シェア分析
  • 主な戦略
  • 競合リーダーシップマッピング

第11章 企業プロファイル

  • BIOGEN
  • SAREPTA THERAPEUTICS
  • GILEAD SCIENCES, INC.
  • AMGEN, INC.
  • NOVARTIS AG
  • ORCHARD THERAPEUTICS PLC
  • SPARK THERAPEUTICS, INC. (‎F. HOFFMANN-LA ROCHEの一部)
  • MOLMED S.P.A.
  • ANGES, INC.
  • BLUEBIRD BIO, INC.
  • JAZZ PHARMACEUTICALS PLC
  • DYNAVAX TECHNOLOGIES
  • HUMAN STEM CELLS INSTITUTE
  • SIBIONO GENETECH CO., LTD.
  • SHANGHAI SUNWAY BIOTECH CO., LTD.
  • UNIQURE N.V.
  • GENSIGHT BIOLOGICS S.A.
  • CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
  • CELLECTIS
  • SANGAMO THERAPEUTICS
  • MUSTANG BIO
  • AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
  • POSEIDA THERAPEUTICS, INC.

第12章 付録

図表

LIST OF TABLES

  • TABLE 1 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
  • TABLE 2 PRODUCT APPROVALS, 2015-2019
  • TABLE 3 GENE THERAPY MARKET: LIST OF SOME PIPELINE DRUGS
  • TABLE 4 PRICE OF GENE THERAPY PRODUCTS, 2018
  • TABLE 5 GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 6 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 7 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 8 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 9 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 10 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 11 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 12 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 13 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 14 GENE THERAPY MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 15 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 16 GENE THERAPY MARKET FOR AAV VECTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 17 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 18 GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 19 GENE THERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 20 NUMBER OF CANCER PATIENTS, BY TYPE, 2012-2030
  • TABLE 21 GENE THERAPY MARKET FOR CANCER, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 22 GENE THERAPY MARKET FOR HEPATOLOGICAL DISEASES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 23 GENE THERAPY MARKET FOR DMD, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 24 GENE THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 25 GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 26 IN VIVO GENE THERAPY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 27 EX VIVO GENE THERAPY MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 28 GENE THERAPY MARKET, BY REGION, 2017-2024 (USD MILLION) 54  
  • TABLE 29 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 30 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 31 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 32 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 33 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 34 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 35 NORTH AMERICA: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 36 LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES
  • TABLE 37 US FDA GENE THERAPY PRODUCT APPROVALS
  • TABLE 38 US: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 39 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 40 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 41 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 42 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 43 US: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 44 CANADA: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 45 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 46 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 47 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 48 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 49 CANADA: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 50 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 51 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 52 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 53 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 54 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 55 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 56 EUROPE: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 57 GERMANY: INCIDENCE OF HEMATOLOGIC CANCERS, BY TYPE, 2018 VS. 2025
  • TABLE 58 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 59 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION) 66  
  • TABLE 60 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 61 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 62 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 63 GERMANY: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 64 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 65 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 66 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 67 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 68 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 69 FRANCE: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 70 UK: INCIDENCE OF CANCERS, BY TYPE, 2018 VS. 2025
  • TABLE 71 UK: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 72 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 73 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 74 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 75 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 76 UK: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 77 ITALY: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 78 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 79 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 80 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 81 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 82 ITALY: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 83 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 84 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 85 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 86 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 87 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 88 SPAIN: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 89 ROE: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 90 ROE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 91 ROE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION) 77  
  • TABLE 92 ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 93 ROE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 94 ROE: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 102 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 103 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 104 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 105 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 106 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 107 JAPAN: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 108 CHINA: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 109 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 110 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 111 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 112 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 113 CHINA: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 114 REST OF APAC: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 115 REST OF APAC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 116 REST OF APAC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 117 REST OF APAC: RETROVIRAL VECTORS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 118 REST OF APAC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 119 REST OF APAC: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 120 ROW: GENE THERAPY MARKET, BY VECTOR, 2017-2024 (USD MILLION)
  • TABLE 121 ROW: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017-2024 (USD MILLION) 87  
  • TABLE 122 ROW: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017-2024 (USD MILLION)
  • TABLE 123 ROW: GENE THERAPY MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 124 PRODUCT APPROVALS, 2016-2019
  • TABLE 125 ACQUISITIONS, 2016-2019
  • TABLE 126 COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS, 2016-2019
  • TABLE 127 EXPANSIONS, 2016-2019

LIST OF FIGURES

  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3 DATA TRIANGULATION METHODOLOGY
  • FIGURE 4 GENE THERAPY MARKET, BY VECTOR, 2019 VS. 2024 (USD MILLION)
  • FIGURE 5 GENE THERAPY MARKET, BY DELIVERY METHOD, 2019 VS. 2024 (USD MILLION)
  • FIGURE 6 GENE THERAPY MARKET, BY INDICATION, 2019 VS. 2024 (USD MILLION)
  • FIGURE 7 GENE THERAPY MARKET: REGIONAL SNAPSHOT
  • FIGURE 8 HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE MARKET GROWTH
  • FIGURE 9 NON-VIRAL VECTORS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN GENE THERAPY MARKET IN 2018
  • FIGURE 10 COUNTRIES IN NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 11 GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 12 NON-VIRAL VECTORS SEGMENT WILL CONTINUE TO DOMINATE THE GENE THERAPY MARKET DURING THE FORECAST PERIOD
  • FIGURE 13 IN VIVO GENE THERAPY SEGMENT WILL CONTINUE TO DOMINATE THE GENE THERAPY MARKET DURING THE FORECAST PERIOD
  • FIGURE 14 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
  • FIGURE 15 KEY DEVELOPMENTS IN THE GENE THERAPY MARKET
  • FIGURE 16 GENE THERAPY MARKET SHARE ANALYSIS, 2018
  • FIGURE 17 VENDOR COMPARISON MATRIX: GENE THERAPY MARKET
  • FIGURE 18 BIOGEN: COMPANY SNAPSHOT
  • FIGURE 19 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
  • FIGURE 20 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • FIGURE 21 AMGEN, INC.: COMPANY SNAPSHOT
  • FIGURE 22 NOVARTIS AG: COMPANY SNAPSHOT
  • FIGURE 23 SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • FIGURE 24 ANGES, INC.: COMPANY SNAPSHOT
  • FIGURE 25 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT
目次
Product Code: BT 7506

"High incidence of cancer & other target diseases is a major factor driving the growth of the gene therapy market"

The global gene therapy market is projected to reach USD 13.0 billion by 2024 from USD 3.8 billion in 2019, at a CAGR of 27.8% during the forecast period. The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of this market. In addition, the strong product pipeline of market players is expected to offer significant growth opportunities in the coming years. However, the high cost of treatment is expected to hamper market growth to a certain extent in the coming years.

"Neurological diseases segment accounted for the largest share of the gene therapy market, by indication, in 2018"

Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. This can be attributed to the increasing number of gene therapy products being approved for the treatment of neurological diseases and the high market penetration of oligonucleotide-based gene therapies.

"Viral vectors segment to register the highest growth in the gene therapy market during the forecast period"

The gene therapy market, by vector, has been segmented into viral and non-viral vectors. In 2018, the non-viral vectors segment accounted for the largest share of this market. However, the viral vectors segment is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing demand for CAR T-based gene therapies and the rising incidence of cancer.

"North America will continue to dominate the gene therapy market during the forecast period"

Geographically, the market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the gene therapy market, followed by Europe. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
  • By Designation: C-level - 30%, D-level - 34%, and Others - 36%
  • By Region: North America - 50%, Europe - 32%, Asia Pacific - 10%, and Rest of the World - 8%

List of companies profiled in the report:

  • Amgen, Inc. (US)
  • Biogen (US)
  • Novartis AG (Switzerland)
  • Gilead Sciences, Inc. (US)
  • Spark Therapeutics, Inc. (US)
  • MolMed S.p.A. (Italy)
  • Orchard Therapeutics plc. (UK)
  • SiBiono GeneTech Co., Ltd. (China)
  • Alnylam Pharmaceuticals, Inc. (US)
  • Human Stem Cells Institute (Russia)
  • AnGes, Inc. (Japan)
  • Dynavax Technologies (US)
  • Jazz Pharmaceuticals, Inc. (Ireland)
  • Akcea Therapeutics (US)
  • bluebird bio, Inc. (US)
  • uniQure NV (Netherlands)
  • AGTC (US)
  • Mustang Bio (US)
  • Cellectis (France)
  • Poseida Therapeutics, Inc. (US)
  • Sangamo Therapeutics (US)

Research Coverage:

This report provides a detailed picture of the global gene therapy market. It aims at estimating the size and future growth potential of the market across different segments (by vector, indication, delivery method, and region). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. Also, this report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 SECONDARY DATA
    • 2.2.1 SECONDARY SOURCES
  • 2.3 PRIMARY DATA
  • 2.4 MARKET SIZE ESTIMATION
    • 2.4.1 BOTTOM-UP APPROACH
    • 2.4.2 BOTTOM-UP APPROACH FOR THE NON-VIRAL VECTORS AND VIRAL

VECTORS MARKET

    • 2.4.3 GROWTH FORECAST
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 GENE THERAPY MARKET OVERVIEW
  • 4.2 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2018)
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 High incidence of cancer and other target diseases
      • 5.2.1.2 Product approvals
      • 5.2.1.3 Funding for gene therapy research
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Strong product pipeline
    • 5.2.3 CHALLENGES
      • 5.2.3.1 High cost of treatments

6 GENE THERAPY MARKET, BY VECTOR

  • 6.1 INTRODUCTION
  • 6.2 NON-VIRAL VECTORS
    • 6.2.1 OLIGONUCLEOTIDES
      • 6.2.1.1 Oligonucleotides accounted for the largest share of the non-viral vectors market
    • 6.2.2 OTHER NON-VIRAL VECTORS
  • 6.3 VIRAL VECTORS
    • 6.3.1 RETROVIRAL VECTORS
      • 6.3.1.1 Gamma-retroviral vectors
        • 6.3.1.1.1 Availability of a wide range of gamma-retroviral vectors supporting market growth
      • 6.3.1.2 Lentiviral vectors
        • 6.3.1.2.1 North America accounted for the largest share of the lentiviral vectors market
    • 6.3.2 ADENO-ASSOCIATED VIRUS VECTORS
      • 6.3.2.1 Possible use in in vivo applications has driven interest in adeno-associated virus vectors
    • 6.3.3 OTHER VIRAL VECTORS

7 GENE THERAPY MARKET, BY INDICATION

  • 7.1 INTRODUCTION
  • 7.2 NEUROLOGICAL DISEASES
    • 7.2.1 NEUROLOGICAL DISEASES FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET
  • 7.3 CANCER
    • 7.3.1 DEMAND FOR GENE THERAPIES FOR THE TREATMENT OF CANCER TO GROW AT A HIGH RATE
  • 7.4 HEPATOLOGICAL DISEASES
    • 7.4.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS WILL SUPPORT MARKET GROWTH
  • 7.5 DUCHENNE MUSCULAR DYSTROPHY
    • 7.5.1 RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH
  • 7.6 OTHER INDICATIONS

8 GENE THERAPY MARKET, BY DELIVERY METHOD

  • 8.1 INTRODUCTION
  • 8.2 IN VIVO GENE THERAPY
    • 8.2.1 IN VIVO GENE THERAPY SEGMENT TO DOMINATE THE MARKET
  • 8.3 EX VIVO GENE THERAPY
    • 8.3.1 EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD

9 GENE THERAPY MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
      • 9.2.1.1 The US dominates the global gene therapy market
    • 9.2.2 CANADA
      • 9.2.2.1 Growing burden of cancer will support market growth in Canada
  • 9.3 EUROPE
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany accounted for the largest share of the market in Europe
    • 9.3.2 FRANCE
      • 9.3.2.1 Increasing cancer incidence to support market growth
    • 9.3.3 UK
      • 9.3.3.1 Rising incidence of melanoma will support market growth in the UK
    • 9.3.4 ITALY
      • 9.3.4.1 High incidence of targeted diseases and increasing per capita healthcare spending will drive market growth in Italy
    • 9.3.5 SPAIN
      • 9.3.5.1 Rising cancer incidence and increasing healthcare expenditure to support market growth in Spain
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 JAPAN
      • 9.4.1.1 Japan dominates the APAC market for gene therapy
    • 9.4.2 CHINA
      • 9.4.2.1 Rising prevalence of cancer and established base for gene therapy to support market growth in China
    • 9.4.3 REST OF ASIA PACIFIC
  • 9.5 REST OF THE WORLD

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 MARKET SHARE ANALYSIS, 2018
  • 10.3 KEY STRATEGIES
  • 10.4 COMPETITIVE LEADERSHIP MAPPING (2018)
    • 10.4.1 VISIONARY LEADERS
    • 10.4.2 INNOVATORS
    • 10.4.3 DYNAMIC DIFFERENTIATORS
    • 10.4.4 EMERGING COMPANIES

11 COMPANY PROFILES

(Business overview, Products offered, Recent developments & MnM View)*

  • 11.1 BIOGEN
  • 11.2 SAREPTA THERAPEUTICS
  • 11.3 GILEAD SCIENCES, INC.
  • 11.4 AMGEN, INC.
  • 11.5 NOVARTIS AG
  • 11.6 ORCHARD THERAPEUTICS PLC
  • 11.7 SPARK THERAPEUTICS, INC. (A PART OF ‎F. HOFFMANN-LA ROCHE)
  • 11.8 MOLMED S.P.A.
  • 11.9 ANGES, INC.
  • 11.10 BLUEBIRD BIO, INC.
  • 11.11 JAZZ PHARMACEUTICALS PLC
  • 11.12 DYNAVAX TECHNOLOGIES
  • 11.13 HUMAN STEM CELLS INSTITUTE
  • 11.14 SIBIONO GENETECH CO., LTD.
  • 11.15 SHANGHAI SUNWAY BIOTECH CO., LTD.
  • 11.16 UNIQURE N.V.
  • 11.17 GENSIGHT BIOLOGICS S.A.
  • 11.18 CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
  • 11.19 CELLECTIS
  • 11.20 SANGAMO THERAPEUTICS
  • 11.21 MUSTANG BIO
  • 11.22 AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
  • 11.23 POSEIDA THERAPEUTICS, INC.

Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS